La obesidad se ha convertido en un serio problema de salud pública. En este oportuno ensayo, Naief Yehya nos ofrece un ...

Un nuevo fármaco llena de esperanzas a quienes padecen diabetes y obesidad: una pastilla de uso diario. Promete los mismos resultados que sus predecesoras inyectadas.

Zepbound (tirzepatide) is a once-a-week injectable weight-loss medication. It helps reduce your appetite by influencing two hormones: glucagon-like peptide-1 (GLP-1) and glucose-dependent ...

No, this isn’t some late-night infomercial fantasy — it’s the reality of Zepbound, and it’s changing everything about how we approach weight loss. While you’ve been cycling through diets ...

This is partly thanks to Zepbound, a weight loss medicine that's already generating more than $1 billion in quarterly sales, although it was approved only in late 2023. Zepbound's prospects still ...

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its diabetes treatment Mounjaro, escalating its battle against unauthorized ...

There are other reasons to invest in the pharmaceutical leader. Zepbound's prospects still look bright, but some recent developments point to another weight loss drug that could become yet another ...

Eli Lilly is suing four telehealth companies selling compounded versions of the pharmaceutical giant's weight loss drug Zepbound and its diabetes treatment Mounjaro, the company's latest attempt ...

Lilly sells tirzepatide as Mounjaro for type 2 diabetes and Zepbound for obesity. In the complaints, Lilly alleges that the telemedicine companies are marketing tirzepatide mixed with substances ...